Navigation Links
When statins aren't enough: New trial drug points to better management of coronary heart disease
Date:5/8/2008

(PHILADELPHIA) Despite widespread use of cholesterol-lowering drugs, a significant number of cardiac patients continue to suffer heart attacks and stroke. Researchers theorize that high levels of an enzyme found in coronary plaques may be to blame, by making plaques more likely to rupture and block blood flow. The drug darapladib may offer a way to fight that risk, according to new research led by the University of Pennsylvania School of Medicine.

Researchers at the Penn and several other international sites have found that the drug may be a useful adjunct to treatment with statin drugs. The new findings, published in a recent issue of the Journal of the American College of Cardiology, show that the drug safely and effectively lowers the activity of Lp-PLA2, an enzyme associated with inflammation activity and an increased risk for heart attack and stroke.

The trial results pave the way for an important addition to the drugs doctors use to treat heart disease, says the studys lead author, Emile R. Mohler, MD, Director of Vascular Medicine and Associate Professor of Medicine at Penn.

This is an exciting new area of medical treatment for cardiovascular disease," Mohler says. "It is hoped that this drug will stabilize artery plaque and prevent heart attack and stroke."

The drug was tested at three different dosage levels in about 1,000 patients with coronary heart disease already taking a cholesterol-lowering statin drug. Among patients taking 160 mg of darapladib each day during the 12-week study, blood tests revealed a decrease in two important circulating biomarkers, suggesting a possible reduction in systemic inflammatory burden.

While the drug doesnt necessarily act to shrink the plaques that build inside coronary arteries and choke off blood supply to the heart, Mohler says the research suggests that darapladib may reduce plaque inflammation and therefore lower rates of clot formation and heart attacks among patients with coronary heart disease.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Stopping Statins After Stroke Doubles Death Risk
2. Research to shed new light on how statins benefit heart patients
3. Statins reduce loss of function, keeping old lungs young - even in smokers
4. Better Prostate Cancer Survival for Men Taking Statins
5. Statins After Bypass Lower Stroke Risk
6. Latest Study Says Statins Dont Slow Alzheimers
7. New Gene-Based Therapy an Alternative to Vytorin and Statins in Heart Disease Prevention and Treatment
8. Tendon complications, though rare, linked to statins
9. Cholesterol-Lowering Statins Tied to Tendon Woes
10. Women are treated less frequently than men with statins, aspirin and beta-blockers
11. iGuard.org Presents New Data on Statins at FDA Workshop Demonstrating How Patient-Reported Information Can Enhance Drug Safety Knowledge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, customers ... Mart has stated to offer wearable, and customers can find clothing at discounted ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global Lyme Alliance ... research, education and awareness, today announced the appointment of Timothy J. Sellati, Ph.D. ... Sellati has more than 20 years of research experience with Lyme and other ...
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center ... pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as one of ... an annual award that was started in 2003 to salute young achievers in Southwest ...
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about personal safety ... the end of November. , The Chicago, Illinois, based self-defense brand has been waiting ... about the ease of taking their personal safety into their own hands. , The ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up ... , In the competitive world of drug and device marketing and promotion, drug ... FDA rules. , The FDA has issued two draft guidances that are the ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
(Date:9/5/2017)... 2017  Just 18 months after its February 2016 ... announce the appointment of three new senior people to ... Dominic Jones-Phillips and James Wright bring ... Tammy Wynne joins as ... writers. She has over ten years, experience in global ...
Breaking Medicine Technology: